Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states
Top Cited Papers
- 21 January 2007
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 13 (2), 204-210
- https://doi.org/10.1038/nm1536
Abstract
Skeletal muscle has the ability to achieve rapid repair in response to injury or disease1. Many individuals with Marfan syndrome (MFS), caused by a deficiency of extracellular fibrillin-1, exhibit myopathy and often are unable to increase muscle mass despite physical exercise. Evidence suggests that selected manifestations of MFS reflect excessive signaling by transforming growth factor (TGF)-β (refs. 2,3). TGF-β is a known inhibitor of terminal differentiation of cultured myoblasts; however, the functional contribution of TGF-β signaling to disease pathogenesis in various inherited myopathic states in vivo remains unknown4,5. Here we show that increased TGF-β activity leads to failed muscle regeneration in fibrillin-1–deficient mice. Systemic antagonism of TGF-β through administration of TGF-β–neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and function in vivo. Moreover, we show TGF-β–induced failure of muscle regeneration and a similar therapeutic response in a dystrophin-deficient mouse model of Duchenne muscular dystrophy. NOTE: In the version of this article initially published, the same panels were inadvertently used to show negative pSmad2/3 and periostin staining in muscle of Fbn1C1039G/+ mice treated with TGF-β‐neutralizing antibody in both the steady-state (Fig. 1a, right column, second and third rows, respectively) and muscle-regeneration (Fig. 1b, right column, third and fourth rows, respectively) experiments. In reality, these images only relate to the steady-state experiment (Fig. 1a). The intended images for Figure 1b are provided (red, pSmad2/3 staining; green, periostin staining). As both sets of images show negative staining in neutralizing antibody–treated Fbn1C1039G/+ mice, this does not alter any observations or conclusions discussed in the manuscript. The error has been corrected in the HTML and PDF versions of the article.Keywords
This publication has 31 references indexed in Scilit:
- Angiotensin II as candidate of cardiac cachexiaCurrent Opinion in Clinical Nutrition and Metabolic Care, 2006
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatmentAmerican Journal of Physiology-Cell Physiology, 2006
- Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditionsBiochemical and Biophysical Research Communications, 2005
- Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouseNeuromuscular Disorders, 2004
- Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosisMuscle & Nerve, 2003
- Loss of myostatin attenuates severity of muscular dystrophy in mdx miceAnnals of Neurology, 2002
- Functional improvement of dystrophic muscle by myostatin blockadeNature, 2002
- Targetting of the gene encoding fibrillin–1 recapitulates the vascular aspect of Marfan syndromeNature Genetics, 1997
- Regulation of myogenic differentiation by type beta transforming growth factor.The Journal of cell biology, 1986